Promore Pharma AB (publ) Interim report January - September 2018
July to September · Net sales amounted to 1.0 (0) MSEK . · The operating loss for the period was 7.4 (-4.4) MSEK · Net loss was 7.6 (-4.8) MSEK, corresponding to a loss per share of SEK-0.38 (-0.24) · Cash flow from operating activities amounted to -6.7 (-15.2) MSEK · Cash and cash equivalents amounted to 39.5 (72.6) MSEK January to September · Net sales amounted to 1.1 (0) MSEK . · The operating loss for the period was 26.1 MSEK (0.9) MSEK · Net loss was 25.3 (2.5) MSEK, corresponding to a loss per share of SEK -1.25 (0.16) · Cash flow from operating